Nuvation Bio
NYSE · NUVB·New York, NY·Small-cap·Approved
Global oncology company with one approved product, IBTROZI (taletrectinib), a next-generation ROS1 inhibitor for advanced ROS1-positive NSCLC, and a clinical pipeline led by safusidenib, a brain-penetrant mIDH1 inhibitor in glioma.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Nuvation Bio Corporate Presentation — September 2026 | Corporate overview | September 18, 2026 | 34 | Source |
| Nuvation Bio Corporate Presentation — January 2026 | Corporate overview | January 13, 2026 | 37 | Source |